Edap Tms

Edap Tms CROIC

The Cash Return on Invested Capital (CROIC) of Edap Tms (EDAP) as of Oct 26, 2026 is -49.63 %. In the previous year, Cash Return on Invested Capital (CROIC) was -34.86 % — a change of 42.35% (lower).

CROIC

-49.63 %

YoY

42.35%

Last updated:

Cash Return on Invested Capital (CROIC) of Edap Tms is 2025 -49.63 % . Cash Return on Invested Capital (CROIC) of Edap Tms was 2024 -34.86 % . It decreases by 42.35% lower compared to the previous year.

The Edap Tms CROIC history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CROIC
Date
CROIC
Jan 1, 2018
-5.49 EUR
Jan 1, 2019
7.22 EUR
Jan 1, 2020
4.82 EUR
Jan 1, 2021
4.88 EUR
Jan 1, 2022
-6.66 EUR
Jan 1, 2023
-30.26 EUR
Jan 1, 2024
-34.86 EUR
Jan 1, 2025
-49.63 EUR
The Edap Tms CROIC history
YEARCROICYoY
-49.63 %+42.35%
-34.86 %+15.23%
-30.26 %+354.34%
-6.66 %-236.34%
4.88 %+1.31%
4.82 %-33.22%
7.22 %-231.40%
-5.49 %-68.63%
-17.51 %+2,202.08%
-0.76 %-120.34%
3.74 %-133.37%
-11.20 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Edap Tms Stock analysis

What does Edap Tms do? Edap Tms SA is a French company specialized in the development and marketing of medical devices. The company was founded in 1979 and has its headquarters in Vaulx-en-Velin, France. With over 300 employees, Edap Tms SA operates worldwide and has branches in the USA, Asia, and Europe. The company's business model is based on the development of non-invasive medical devices, particularly HIFU (High-Intensity Focused Ultrasound) devices. With its technology, the company has developed a revolutionary new procedure for tumor treatment that can replace traditional radiation therapy. HIFU offers a gentler and more precise alternative for tumor treatment without damaging the surrounding tissue. Edap Tms SA offers its products and services in four main business areas: 1. HIFU systems for the treatment of prostate cancer: Edap Tms SA has developed a HIFU system capable of treating prostate cancer without invasive procedures. The system uses a special ultrasound probe inserted into the rectum to locate the tumor and direct targeted sound waves at the tumor, destroying cancer cells. 2. HIFU systems for the treatment of kidney cancer: Edap Tms SA has also developed a HIFU system capable of treating kidney cancer tumors. It works similarly to the prostate cancer system, effectively destroying the tumor through targeted sound waves. 3. Mobile HIFU devices: Edap Tms SA has developed mobile HIFU devices suitable for use in hospitals and clinics. These devices can be quickly and easily transported from room to room, allowing medical professionals to perform HIFU treatments without the need for additional equipment. 4. Bladder cancer treatment technology: Edap Tms SA has also developed technology used in the treatment of bladder cancer. The system also utilizes HIFU technology to destroy tumor cells, but it is introduced through the urethra and focuses on the tumor in the bladder. Edap Tms SA is a global leader in the development and marketing of HIFU systems. The company aims to improve cancer treatment and provide patients with a more effective and gentler alternative to traditional radiation therapy. With a wide range of products suitable for various types of cancer and a strong presence in the USA, Europe, and Asia, Edap Tms SA is a highly regarded brand in the medical device field. Overall, Edap Tms SA is a company with a rich history that focuses on innovative technologies and continuously strives to improve the lives of cancer patients. With its HIFU portfolio and strong market presence, the company is on track to achieve its goals and solidify its position as one of the leading providers of medical devices worldwide. Edap Tms is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Edap Tms stock

Cash Return on Invested Capital (CROIC) of Edap Tms is -49.63 % in 2025.

Cash Return on Invested Capital (CROIC) of Edap Tms changed from -34.86 % to -49.63 %, representing a 42.35% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Return on Invested Capital (CROIC) Edap Tms since 2006 – with annual values, charts, and detailed analysis.

CROIC measures the cash return generated on invested capital. Unlike ROIC, it uses free cash flow instead of accounting earnings, providing a purer profitability measure.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Return on Invested Capital (CROIC)'s Edap Tms with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Return on Invested Capital (CROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Return on Invested Capital (CROIC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Edap Tms

All Key Metrics — Edap Tms